Philip Badman

464 total citations
7 papers, 136 citations indexed

About

Philip Badman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Philip Badman has authored 7 papers receiving a total of 136 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Philip Badman's work include Advanced Breast Cancer Therapies (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Ovarian cancer diagnosis and treatment (2 papers). Philip Badman is often cited by papers focused on Advanced Breast Cancer Therapies (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Ovarian cancer diagnosis and treatment (2 papers). Philip Badman collaborates with scholars based in United Kingdom, Spain and United States. Philip Badman's co-authors include Susan Philpott, Usha Menon, Richard Hadwin, Ian Jacobs, Diana Eccles, James Mackay, Ranjit Manchanda, D. Gareth Evans, Steven J. Skates and Adam N. Rosenthal and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Breast Cancer Research and Treatment.

In The Last Decade

Philip Badman

6 papers receiving 126 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip Badman United Kingdom	4	78	55	43	32	30	7	136
Marieke G. M. Braem Netherlands	4	55 0.7×	30 0.5×	55 1.3×	20 0.6×	26 0.9×	4	135
Brigitte Clavier France	5	71 0.9×	44 0.8×	33 0.8×	40 1.3×	14 0.5×	7	153
C. Brunell United Kingdom	6	140 1.8×	126 2.3×	33 0.8×	35 1.1×	57 1.9×	8	212
Mae Zakhour United States	6	118 1.5×	57 1.0×	56 1.3×	35 1.1×	80 2.7×	17	237
T. Tillmanns United States	4	34 0.4×	100 1.8×	23 0.5×	18 0.6×	50 1.7×	10	168
Raluca Nedelcu United States	4	126 1.6×	121 2.2×	35 0.8×	21 0.7×	34 1.1×	6	195
Marion Piedmonte United States	4	73 0.9×	56 1.0×	53 1.2×	14 0.4×	19 0.6×	4	155
Marline G. Harmsen Netherlands	11	168 2.2×	155 2.8×	41 1.0×	30 0.9×	66 2.2×	15	259
Jakkapan Khunnarong Thailand	11	87 1.1×	31 0.6×	57 1.3×	26 0.8×	117 3.9×	26	234
Claire Hoppenot United States	7	80 1.0×	15 0.3×	54 1.3×	28 0.9×	31 1.0×	11	163

Countries citing papers authored by Philip Badman

Since Specialization

Citations

This map shows the geographic impact of Philip Badman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Badman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Badman more than expected).

Fields of papers citing papers by Philip Badman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Badman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Badman. The network helps show where Philip Badman may publish in the future.

Co-authorship network of co-authors of Philip Badman

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Badman. A scholar is included among the top collaborators of Philip Badman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Badman. Philip Badman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Allsopp, Rebecca C., Qi Guo, Karen Page, et al.. (2024). Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study. Breast Cancer Research and Treatment. 206(2). 377–385. 2 indexed citations

Ghorani, Ehsan, Matteo Quartagno, Fiona Blackhall, et al.. (2023). REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment. The Lancet Oncology. 24(5). e219–e227. 13 indexed citations

Lythgoe, Mark P., Paola Dama, Adam E. Frampton, et al.. (2023). Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naïve patients with cancer: Updated safety data.. Journal of Clinical Oncology. 41(16_suppl). 3145–3145. 3 indexed citations

Seckl, Michael J., Philip Badman, Xinxue Liu, et al.. (2017). RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitors (AIs).. Journal of Clinical Oncology. 35(15_suppl). 1059–1059. 14 indexed citations

Rosenthal, Adam N., Lindsay Fraser, Ranjit Manchanda, et al.. (2013). RESULTS OF INTENSIVE ALGORITHM-BASED SCREENING IN THE UK FAMILIAL OVARIAN CANCER SCREENING STUDY (UK FOCSS PHASE 2). International Journal of Gynecological Cancer. 1 indexed citations

Rosenthal, Adam N., Lindsay Fraser, Susan Philpott, et al.. (2013). Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS Phase 2).. Journal of Clinical Oncology. 31(15_suppl). 5507–5507. 8 indexed citations

Rosenthal, Adam N., Lindsay Fraser, Ranjit Manchanda, et al.. (2012). Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. Journal of Clinical Oncology. 31(1). 49–57. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact